Skip to main content
Caplight Logo









BioTryp Therapeutics

BioTryp Therapeutics

Private
CambridgeHealthcare & Life Scienceshttps://biotryp.com/

Last Round

Grant

Nov 24, 2025

Total Funding Raised

$940,000

Momentum

Top 50%

of companies Caplight tracks

Company Overview

BioTryp Therapeutics is a biotechnology company developing novel oral antibiofilm therapies for bacterial infections.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting, Government Contracts

AI Layer

Application

Keywords

anti-biofilm therapysmall-molecule inhibitorbacterial biofilmantibiotic resistancesuperbugsurinary tract infectionUTIpreclinical drug discoveryantibiotic enhancernon-antibiotic therapydrug licensingbiotechbiofilm busterAI drug discoverymedicinal chemistry

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

BioTryp Therapeutics Comparables

Compare BioTryp Therapeutics with similar companies based on industry and business-model similarity.

BioTryp Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Disperazol Pharma ApS
88%
Fimbrion Therapeutics
81%
Resistia
80%

BioTryp Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantNov 24, 2025
Pre SeedAug 15, 2024

Key People

Founding team and executive leadership

Ashraf Zarkan

CEO & Co-Founder

Founding Team

BioTryp Therapeutics Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Nov 24, 2025

    $540K raised from Innovate UK and NRC IRAP.

  • Aug 15, 2024

    $400K raised from Parkwalk Advisors and QUBIS.

BioTryp Therapeutics Filings

Explore SEC and related filing metadata, where available.

BioTryp Therapeutics filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about BioTryp Therapeutics's valuation, stock price, and market status.

Is BioTryp Therapeutics a public or private company?

BioTryp Therapeutics is a private company.

What is the current stock price of BioTryp Therapeutics?

BioTryp Therapeutics is a private company with no public stock price. No recent secondary market data is available.

How much is BioTryp Therapeutics worth (valuation)?

Valuation information for BioTryp Therapeutics is not publicly available.

Can I buy BioTryp Therapeutics stock?

BioTryp Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was BioTryp Therapeutics's last funding round?

BioTryp Therapeutics's most recent funding round was Grant on November 24, 2025.

Who are the main investors in BioTryp Therapeutics?

Key investors in BioTryp Therapeutics include Founders at the University of Cambridge, QUBIS, National Research Council Canada Industrial Research Assistance Program, Innovate UK, Cambridge Enterprise.

Will BioTryp Therapeutics IPO soon?

No public IPO plans have been announced for BioTryp Therapeutics.

How can I track BioTryp Therapeutics secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor BioTryp Therapeutics's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersCambridge
Employee Range4
Year Founded2024
Last FundingNov 24, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?